3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 1/2
4
Phase 2
3
Phase NA
1
Phase 3
1
Phase 2/3
1
Status
Completed
2
Not yet recruiting
1
Sponsor Class
OTHER
11
INDUSTRY
3
NIH
2
NETWORK
1
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
3
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
687
Breast Neoplasms
585
Neoplasms
468
Colorectal Neoplasms
300
Prostatic Neoplasms
263
Neoplasm Metastasis
257
Melanoma
242
Ovarian Neoplasms
228
Recurrence
216
Lung Neoplasms
203
Multiple Myeloma
196
Lymphoma, Non-Hodgkin
155
Pancreatic Neoplasms
154
Leukemia, Myeloid, Acute
142
Carcinoma, Hepatocellular
141
Stomach Neoplasms
137
Lymphoma
131
Carcinoma, Renal Cell
128
Glioblastoma
118
Squamous Cell Carcinoma of Head and Neck
113
Head and Neck Neoplasms
113
Lymphoma, Follicular
106
Leukemia, Lymphocytic, Chronic, B-Cell
99
Small Cell Lung Carcinoma
96
Lymphoma, Large B-Cell, Diffuse
96
Leukemia
96
Brain Neoplasms
91
Carcinoma
82
Uterine Cervical Neoplasms
77
Triple Negative Breast Neoplasms
73
Interventions
ixazomib
1
birtamimab
1
belantamab mafodotin
1
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
INDUSTRY
×
Amyloidosis
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled
NCT02924272
2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2
Completed
32 enrolled
13 charts
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts